기본 통계
| LEI | 5299000YHQJ21T5KKI80 |
| CIK | 910329 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medifast, Inc.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2026 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware 001-31573 13-3714405 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 1, 2026 |
SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) is made by and between Jason Pharmaceuticals, Inc. |
|
| May 26, 2026 |
Date: May 20, 2026 To: Nick Johnson From: Dan Chard Chief Executive Officer & Board Chairman Subject: Promotion CC: Personnel file of Nick Johnson Dear Nick, Congratulations on your promotion to Chief Executive Officer effective June 8, 2026. |
|
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware 001-31573 13-3714405 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 26, 2026 |
MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN 1.Purpose. The purpose of this Amended and Restated 2012 Share Incentive Plan (the “Plan”) of Medifast, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company and its stockholders by providing a means to attract, retain, and reward executive officers and other key individuals of the Company and/or its s |
|
| May 26, 2026 |
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board BALTIMORE — May 26, 2026 — Medifast, Inc. |
|
| May 4, 2026 |
Exhibit 10.7 Medifast, Inc. Amended and Restated 2012 Share Incentive Plan DEFERRED SHARE EMPLOYEE AWARD AGREEMENT (STANDARD) Pursuant to your Deferred Share Grant Notice (“Grant Notice”) and this Award Agreement, Medifast, Inc. (the “Company”) has granted to you Deferred Shares (“RSUs” or “Award”) under the Plan covering the number of RSUs indicated in your Grant Notice, which vest in accordance |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714405 |
|
| May 4, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 |
|
| May 4, 2026 |
Medifast Announces First Quarter 2026 Financial Results Medifast Announces First Quarter 2026 Financial Results May 4, 2026 BALTIMORE – (BUSINESS WIRE)-Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. |
|
| May 4, 2026 |
Exhibit 10.3 MEDIFAST, INC. DIRECTORS’ DEFERRED COMPENSATION PLAN (AMENDED AND RESTATED) EFFECTIVE AS OF March 18, 2021 AMENDED AS OF March 12, 2026 Article I. Introduction Section 1.01 Purpose. This Plan is being established by Medifast, Inc. (the “Company”) to assist the Company in attracting and retaining well-qualified directors who are not officers or employees of the Company or any subsidiar |
|
| May 4, 2026 |
Exhibit 10.4 Medifast, Inc. Amended and Restated 2012 Share Incentive Plan PERFORMANCE SHARE UNITS AWARD AGREEMENT (CEO AND CEO DIRECT REPORTS) Pursuant to your Performance Share Units Grant Notice (“Grant Notice”) and this Award Agreement, Medifast, Inc. (the “Company”) has granted to you performance-based Deferred Shares (“Performance Share Units”, “PSUs” or “Award”) under the Plan covering the |
|
| May 4, 2026 |
Exhibit 10.6 Medifast, Inc. Amended and Restated 2012 Share Incentive Plan DEFERRED SHARE EMPLOYEE AWARD AGREEMENT (CEO AND CEO DIRECT REPORTS) Pursuant to your Deferred Share Grant Notice (“Grant Notice”) and this Award Agreement, Medifast, Inc. (the “Company”) has granted to you Deferred Shares (“RSUs” or “Award”) under the Plan covering the number of RSUs indicated in your Grant Notice, which v |
|
| May 4, 2026 |
Exhibit 10.5 Medifast, Inc. Amended and Restated 2012 Share Incentive Plan PERFORMANCE SHARE UNITS AWARD AGREEMENT (STANDARD) Pursuant to your Performance Share Units Grant Notice (“Grant Notice”) and this Award Agreement, Medifast, Inc. (the “Company”) has granted to you performance-based Deferred Shares (“Performance Share Units”, “PSUs” or “Award”) under the Plan covering the number of PSUs ind |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 6, 2026 |
2025 ANNUAL REPORTChairman & Chief Executive Officer This shift represents a natural extension of our decades of expertise in structured, coach- guided health transformation. |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 20, 2026 |
Cooperation Agreement This Cooperation Agreement (this “Agreement”) is made and entered into as of March 19, 2026, by and among Medifast, Inc. |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| March 20, 2026 |
Medifast Announces Cooperation Agreement with Steamboat Capital Company Agrees to Nominate Parsa Kiai and Jeff Rose as Director Candidates at 2026 Annual Meeting of Stockholders BALTIMORE, March 20, 2026 - Medifast, Inc. |
|
| February 17, 2026 |
Medifast Announces Fourth Quarter and Full Year 2025 Financial Results Medifast Announces Fourth Quarter and Full Year 2025 Financial Results February 17, 2026 BALTIMORE-(BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| February 17, 2026 |
Subsidiaries of Medifast, Inc. Exhibit 21.1 Subsidiaries of Medifast, Inc. Corporate Subsidiaries State of Incorporation Jason Enterprises, Inc. Delaware Jason Pharmaceuticals, Inc. Maryland Jason Properties, LLC Delaware OPTAVIA LLC Delaware OPTAVIA Health Consultation (Shanghai) Co., Ltd. Shanghai, China OPTAVIA (Hong Kong) Limited Hong Kong |
|
| January 5, 2026 |
Date: January 5, 2026 To: Daniel Chard From: Jeffrey Brown Lead Director of the Board Subject: Change in Compensation and Transition in Position CC: Personnel file of Dan Chard Dear Dan, As you know, the Compensation Committee of the Board of Directors recently updated Medifast’s 2026 executive compensation peer group to reflect the current size, performance, and outlook of the company. |
|
| January 5, 2026 |
SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) is made by and between Jason Pharmaceuticals, Inc. |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2025 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| January 5, 2026 |
Medifast Announces Planned Leadership Transition Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman BALTIMORE, January 5, 2026 - Medifast, Inc. |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31 |
|
| November 3, 2025 |
Medifast Announces Third Quarter 2025 Financial Results Medifast Announces Third Quarter 2025 Financial Results November 3, 2025 BALTIMORE – (BUSINESS WIRE) — Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the third quarter ended September 30, 2025. |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| August 4, 2025 |
Medifast Announces Second Quarter 2025 Financial Results Medifast Announces Second Quarter 2025 Financial Results August 4, 2025 BALTIMORE – (BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2025. |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 M |
|
| August 4, 2025 |
Calculation of Filing Fee Table * Exhibit 107 Calculation of Filing Fee Tables Medifast, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be registered (1) Proposed Maximum Offering Price Per Unit ($)(2) Maximum Aggregate Offering Price ($)(2) Fee Rate Amount of Registration Fee ($) Equity Common Stock, par value $0.001 per share 457(h) 550,000 14.18 7,799,000 0.00015310 1 |
|
| August 4, 2025 |
As filed with the Securities and Exchange Commission on August 4, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| June 20, 2025 |
Amended and Restated 2012 Share Incentive Plan MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN 1.Purpose. The purpose of this Amended and Restated 2012 Share Incentive Plan (the “Plan”) of Medifast, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company and its stockholders by providing a means to attract, retain, and reward executive officers and other key individuals of the Company and/or its s |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware 001-31573 13-3714405 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 5, 2025 |
2024 ANNUAL REPORTChairman & Chief Executive Officer Our holistic and scientifically developed approach is backed by personalized plans, science-formulated products, and the one-on-one support of a coach. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 28, 2025 |
Medifast Announces First Quarter 2025 Financial Results Medifast Announces First Quarter 2025 Financial Results April 28, 2025 BALTIMORE – (BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. |
|
| April 28, 2025 |
Amended and Restated 2012 Share Incentive Plan (filed herewith). MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN 1.Purpose. The purpose of this Amended and Restated 2012 Share Incentive Plan (the “Plan”) of Medifast, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company and its stockholders by providing a means to attract, retain, and reward executive officers and other key individuals of the Company and/or its s |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 |
|
| February 18, 2025 |
Medifast Announces Fourth Quarter and Full Year 2024 Financial Results Medifast Announces Fourth Quarter and Full Year 2024 Financial Results February 18, 2025 BALTIMORE-(BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. |
|
| February 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. |
|
| February 18, 2025 |
Subsidiaries of Medifast, Inc. (filed herewith). Exhibit 21.1 Subsidiaries of Medifast, Inc. Corporate Subsidiaries State of Incorporation Jason Enterprises, Inc. Delaware Jason Pharmaceuticals, Inc. Maryland Jason Properties, LLC Delaware OPTAVIA LLC Delaware OPTAVIA Health Consultation (Shanghai) Co., Ltd. Shanghai, China OPTAVIA (Hong Kong) Limited Hong Kong |
|
| February 18, 2025 |
Medifast, Inc. Insider Trading Policy Amended and Restated (filed herewith). MEDIFAST, INC. INSIDER TRADING POLICY I.Purpose, Scope, Compliance, and Definitions & Explanations A.Overview and Purpose This Insider Trading Policy (the “Policy”) is intended to promote compliance with applicable securities laws and to provide the directors, officers (as such term is defined pursuant to Section 16 of the Securities Exchange Act of 1934), and employees of Medifast, Inc. (together |
|
| January 13, 2025 |
January 13, 2025 Jonathan Mackenzie Chief Accounting Officer Medifast, Inc. 100 International Drive Baltimore, MD 21202 Re: Medifast, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-31573 Dear Jonathan Mackenzie: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, |
|
| January 2, 2025 |
January 2, 2025 Stephany Yang and Melissa Gilmore Division of Corporate Finance Office of Manufacturing U. |
|
| December 19, 2024 |
December 19, 2024 Jonathan Mackenzie Chief Accounting Officer Medifast, Inc. 100 International Drive Baltimore, MD 21202 Re: Medifast, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Response Dated November 26, 2024 File No. 001-31573 Dear Jonathan Mackenzie: We have reviewed your November 26, 2024 response to our comment letter and have the following comments. Please respond to this le |
|
| November 26, 2024 |
November 26, 2024 Stephany Yang and Melissa Gilmore Division of Corporate Finance Office of Manufacturing U. |
|
| November 18, 2024 |
November 18, 2024 Jonathan Mackenzie Chief Accounting Officer Medifast, Inc. 100 International Drive Baltimore, MD 21202 Re: Medifast, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Response Dated October 30, 2024 File No. 001-31573 Dear Jonathan Mackenzie: We have reviewed your October 30, 2024 response to our comment letter and have the following comments. Please respond to this lett |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31 |
|
| November 4, 2024 |
Medifast Announces Third Quarter 2024 Financial Results Medifast Announces Third Quarter 2024 Financial Results November 4, 2024 BALTIMORE – (BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware 001-31573 13-3714405 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 31, 2024 |
As filed with the Securities and Exchange Commission on October 31, 2024 As filed with the Securities and Exchange Commission on October 31, 2024 Registration No. |
|
| October 31, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Medifast, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount to be registered (1) Proposed Maximum Offering Price Per Unit ($)(2) Maximum Aggregate Offering Price ($)(2) Fee Rate Amount of Registration Fee ($) Equity Common Stock, par value $0.001 per share 457(h) 515,000 17.74 9,136,100 0.00015310 1 |
|
| October 30, 2024 |
October 30, 2024 Via EDGAR Correspondence Stephany Yang and Melissa Gilmore Division of Corporate Finance Office of Manufacturing U. |
|
| October 30, 2024 |
October 30, 2024 Stephany Yang and Melissa Gilmore Division of Corporate Finance Office of Manufacturing U. |
|
| October 17, 2024 |
October 17, 2024 Jonathan Mackenzie Chief Accounting Officer Medifast, Inc. 100 International Drive Baltimore, MD 21202 Re: Medifast, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 20, 2024 Form 10-Q for the Fiscal Quarter Ended June 30, 2024 Filed August 5, 2024 File No. 001-31573 Dear Jonathan Mackenzie: We have limited our review of your filing to the financial statem |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 M |
|
| August 5, 2024 |
Medifast Announces Second Quarter 2024 Financial Results Medifast Announces Second Quarter 2024 Financial Results August 5, 2024 BALTIMORE – (BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. |
|
| July 10, 2024 |
MED / Medifast, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Medifast Inc Title of Class of Securities: Common Stock CUSIP Number: 58470H101 Date of Event Which Requires Filing of this Statement: June 28, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d- |
|
| July 8, 2024 |
MED / Medifast, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us58470h1014070824.txt us58470h1014070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 18) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| July 1, 2024 |
MED / Medifast, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 MEDSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MEDIFAST, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 58470H101 (CUSIP Number) JUNE 27, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware 001-31573 13-3714405 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 21, 2024 |
Amended and Restated 2012 Share Incentive Plan Exhibit 10.1 MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN 1.Purpose. The purpose of this Amended and Restated 2012 Share Incentive Plan (the “Plan”) of Medifast, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company and its stockholders by providing a means to attract, retain, and reward executive officers and other key individuals of the Company |
|
| May 8, 2024 | ||
| April 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| April 29, 2024 |
Medifast Announces First Quarter 2024 Financial Results Medifast Announces First Quarter 2024 Financial Results April 29, 2024 BALTIMORE – (BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2024. |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 20, 2024 |
Medifast, Inc. Clawback Policy Amended and Restated Exhibit 97 MEDIFAST, INC. CLAWBACK POLICY AMENDED AND RESTATED Introduction The Board of Directors (the “Board) of Medifast, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay for performance compensation philosophy. The Board has there |
|
| February 20, 2024 |
Subsidiaries of Medifast, Inc. (filed herewith). Exhibit 21.1 Subsidiaries of Medifast, Inc. Corporate Subsidiaries State of Incorporation Corporate Events, Inc. Delaware Jason Enterprises, Inc. Delaware Jason Pharmaceuticals, Inc. Maryland Jason Properties, LLC Delaware OPTAVIA LLC Delaware OPTAVIA Health Consultation (Shanghai) Co., Ltd. Shanghai, China OPTAVIA (Hong Kong) Limited Hong Kong OPTAVIA (Singapore) PTE. LTD Singapore Seven Crondall |
|
| February 20, 2024 |
Medifast Announces Fourth Quarter and Full Year 2023 Financial Results Medifast Announces Fourth Quarter and Full Year 2023 Financial Results February 20, 2024 BALTIMORE-(BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2023. |
|
| February 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| February 20, 2024 |
Exhibit 32 MEDIFAST, INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Medifast, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel R. Chard, Chief Executive Officer, a |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. |
|
| February 13, 2024 |
MED / Medifast, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01435-medifastinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Medifast Inc Title of Class of Securities: Common Stock CUSIP Number: 58470H101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 13, 2024 |
MED / Medifast, Inc. / RENAISSANCE TECHNOLOGIES LLC Passive Investment SC 13G/A 1 med-13g20231231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* Medifast, Inc. - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 29, 2023 - (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| January 22, 2024 |
MED / Medifast, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us58470h1014012224.txt us58470h1014012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 17) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| December 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| December 13, 2023 |
Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, a Virtual Primary Care Provider, and Adjusting its Capital Allocation Policy Health and wellness company makes $20 million capital commitment to LifeMD, enters medically supported weight loss market projected to reach up to $100 billion by 2030 Company discontinues quarterly cash dividend and intends to invest in initiatives aimed at driving customer acquisition and customer experience to reignite growth Conference call to discuss Medifast and LifeMD collaboration begins at 10 AM EST today BALTIMORE, Dec. |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31 |
|
| November 6, 2023 |
Medifast Announces Third Quarter 2023 Financial Results Medifast Announces Third Quarter 2023 Financial Results November 6, 2023 BALTIMORE-(BUSINESS WIRE)-Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2023. |
|
| September 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13- |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| September 7, 2023 |
Medifast Announces Quarterly Dividend Medifast Announces Quarterly Dividend BALTIMORE - September 7, 2023 /PRNewswire/ - Medifast (NYSE: MED), the company behind the health and wellness community, OPTAVIA®, today announced that its Board of Directors has declared a $1. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 M |
|
| August 7, 2023 |
Medifast Announces Second Quarter 2023 Financial Results Medifast Announces Second Quarter 2023 Financial Results BALTIMORE - August 7, 2023 /PRNewswire/ - Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA® , today reported results for the second quarter ended June 30, 2023. |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37144 |
|
| June 15, 2023 |
Medifast Announces Quarterly Dividend Medifast Announces Quarterly Dividend BALTIMORE - June 15, 2023 /PRNewswire/ - Medifast (NYSE: MED), the company behind the health and wellness community, OPTAVIA®, today announced that its Board of Directors has declared a $1. |
|
| June 1, 2023 |
Medifast Enhances “Fuel for the Future” Program to Position the Business for Long-term Sustainable Growth Optimizations aimed at freeing up capital to invest in growth initiatives expected to triple the company’s addressable market BALTIMORE - June 1, 2023 /PRNewswire/ - Medifast (NYSE: MED), the company behind the health and wellness community, OPTAVIA®, today announced further strategic changes to enhance its Fuel for the Future program, which optimizes spending through value engineering, operational efficiency and improved procurement. |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-371440 |
|
| May 1, 2023 |
Medifast Announces First Quarter 2023 Financial Results Medifast Announces First Quarter 2023 Financial Results BALTIMORE - May 1, 2023 /PRNewswire/ - Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the first quarter ended March 31, 2023. |
|
| May 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714405 |
|
| May 1, 2023 |
2022 ANNUAL REPORTChairman & Chief Executive Officer Our vision is a world in which people are empowered and able to transform their health and wellness for the long-term, as part of a deep and engaged community. |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| March 16, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| March 16, 2023 |
Medifast Announces Quarterly Dividend Medifast Announces Quarterly Dividend BALTIMORE - March 16, 2023 /PRNewswire/ - Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that its Board of Directors has declared a $1. |
|
| February 21, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| February 21, 2023 |
Medifast Announces Fourth Quarter and Full Year 2022 Financial Results Full year revenue increases; active earning Coaches increase in Q4 as customer retention rates further stabilize BALTIMORE - February 21, 2023 /PRNewswire/ - Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the fourth quarter ended December 31, 2022. |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. |
|
| February 21, 2023 |
Subsidiaries of Medifast, Inc. (filed herewith). Exhibit 21.1 Subsidiaries of Medifast, Inc. Corporate Subsidiaries State of Incorporation Corporate Events, Inc. Delaware Jason Enterprises, Inc. Delaware Jason Pharmaceuticals, Inc. Maryland Jason Properties, LLC Delaware OPTAVIA, LLC Delaware OPTAVIA Health Consultation (Shanghai) Co., Ltd. Shanghai, China OPTAVIA (Hong Kong) Limited Hong Kong OPTAVIA (Singapore) PTE. LTD Singapore Seven Crondal |
|
| February 13, 2023 |
MED / Medifast Inc / RENAISSANCE TECHNOLOGIES LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Medifast, Inc. - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 9, 2023 |
MED / Medifast Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01401-medifastinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Medifast Inc. Title of Class of Securities: Common Stock CUSIP Number: 58470H101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| January 26, 2023 |
MED / Medifast Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us58470h1014012623.txt us58470h1014012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 16) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 20, 2023 |
MED / Medifast Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us58470h1014012023.txt us58470h1014012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 15) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| December 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| December 8, 2022 |
Medifast Announces Quarterly Dividend Medifast Announces Quarterly Dividend BALTIMORE - December 8, 2022 /PRNewswire/ - Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today that its Board of Directors has declared a $1. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 med-20221103form8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31 |
|
| November 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31 |
|
| November 3, 2022 |
Medifast Announces Third Quarter 2022 Financial Results Customer retention rates return to historical norms; Euromonitor names company the number one weight loss program in the U. |
|
| September 8, 2022 |
Medifast Announces Quarterly Dividend Medifast Announces Quarterly Dividend BALTIMORE, September 8, 2022/PRNewswire/ - Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today that its Board of Directors has declared a $1. |
|
| September 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| August 3, 2022 |
MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN GRANT NOTICE PERFORMANCE SHARE UNITS Medifast, Inc. (the “Company”) hereby grants to the Participant named below performance-based Deferred Shares (“Performance Share Units” or “PSUs”) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the “Plan”) in the number specified below (the “Target Award Opportunity”) |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| August 3, 2022 |
Amendment No. 2 to Medifast, Inc. Executive Severance Plan (filed herewith) MEDIFAST, INC. EXECUTIVE SEVERANCE PLAN Medifast, Inc., a Delaware corporation (the “Company”), has adopted this Medifast, Inc. Executive Severance Plan (the “Plan”) to provide key employees of the Company and its affiliates and subsidiaries with severance protection under covered circumstances. Article 1. DEFINITIONS AND INTERPRETATIONS Section 1.0aDefinitions. Capitalized terms used in this Plan |
|
| August 3, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 M |
|
| August 3, 2022 |
Medifast Announces Second Quarter 2022 Financial Results and Updated Outlook Medifast Announces Second Quarter 2022 Financial Results and Updated Outlook BALTIMORE - August 3, 2022 /PRNewswire/ - Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the second quarter ended June 30, 2022. |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37144 |
|
| June 16, 2022 |
Medifast, Inc. Announces Quarterly Dividend Medifast, Inc. Announces Quarterly Dividend BALTIMORE, June 16, 2022/PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today that its Board of Directors has declared a $1.64 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.64 per share is payable on August 8, 2022 to stoc |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-371440 |
|
| June 3, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of May 31, 2022 (this ?First Amendment?), by and among Medifast, Inc., a Delaware corporation (the ?Borrower?), the other Loan Parties (as defined in the Credit Agreement referred to below), Citibank, N.A., as administrative agent (the ?Administrative Agent?), and the Lenders (as defined below) party to |
|
| June 1, 2022 |
Exhibit 99.1 Medifast, Inc. Announces $100M Accelerated Share Repurchase Program Investment demonstrates confidence in long-term growth model, aligns interests with stockholders BALTIMORE - June 1, 2022 /PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today it has entered into an accelerated share r |
|
| June 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-371440 |
|
| May 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 |
|
| May 2, 2022 |
MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN GRANT NOTICE NONEMPLOYEE DIRECTOR DEFERRED SHARE CASH EQUIVALENT Medifast, Inc. (the ?Company?) hereby grants to the Participant named below Deferred Shares ( ?RSUs?) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the ?Plan?) in the number specified below, which shall vest in accordance with the Vesting S |
|
| May 2, 2022 |
Medifast, Inc. Announces First Quarter 2022 Financial Results Exhibit 99.1 Medifast, Inc. Announces First Quarter 2022 Financial Results BALTIMORE - May 2, 2022 /PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, today reported results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Compared to the Prior-Year Period ?Revenue increased 22.6% to $41 |
|
| May 2, 2022 |
Medifast, Inc. Amended and Restated 2012 Share Incentive Plan MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN GRANT NOTICE PERFORMANCE SHARE UNITS Medifast, Inc. (the ?Company?) hereby grants to the Participant named below performance-based Deferred Shares (?Performance Share Units? or ?PSUs?) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the ?Plan?) in the number specified below (the ?Target Award Opportunity?) |
|
| May 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714405 |
|
| May 2, 2022 |
Medifast, Inc. Amended and Restated 2012 Share Incentive Plan Grant Notice MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN GRANT NOTICE EMPLOYEE DEFERRED SHARES Medifast, Inc. (the ?Company?) hereby grants to the Participant named below Deferred Shares ( ?RSUs?) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the ?Plan?) in the number specified below, which shall vest in accordance with the Vesting Schedule. Each RSU relates a |
|
| May 2, 2022 |
MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN GRANT NOTICE NONEMPLOYEE DIRECTOR DEFERRED SHARES Medifast, Inc. (the ?Company?) hereby grants to the Participant named below Deferred Shares ( ?RSUs?) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the ?Plan?) in the number specified below, which shall vest in accordance with the Vesting Schedule. Each R |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| March 17, 2022 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, March 17, 2022/PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today that its Board of Directors has declared a $1.64 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.64 per share is payable on May 9, 2 |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| February 23, 2022 |
Subsidiaries of Medifast, Inc. (filed herewith). Exhibit 21.1 Subsidiaries of Medifast, Inc. Corporate Subsidiaries State of Incorporation Corporate Events, Inc. Delaware Jason Enterprises, Inc. Delaware Jason Pharmaceuticals, Inc. Maryland Jason Properties, LLC Delaware Medifast Franchise Systems, Inc. Delaware OPTAVIA, LLC Delaware OPTAVIA Health Consultation (Shanghai) Co., Ltd. Shanghai, China OPTAVIA (Hong Kong) Limited Hong Kong OPTAVIA (S |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto. |
|
| February 23, 2022 |
Medifast, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results EX-99.1 2 med-20220223x8kexx991.htm EX-99.1 Exhibit 99.1 Medifast, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results BALTIMORE, Feb. 23, 2022 /PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 20 |
|
| February 11, 2022 |
MED / Medifast Inc / RENAISSANCE TECHNOLOGIES LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Medifast, Inc. - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2022 |
MED / Medifast Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Medifast Inc. Title of Class of Securities: Common Stock CUSIP Number: 58470H101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 27, 2022 |
MED / Medifast Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us58470h1014012722.txt us58470h1014012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| January 26, 2022 |
MED / Medifast Inc / BlackRock Inc. Passive Investment us58470h1014012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 13) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| December 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| December 8, 2021 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, December 8, 2021/PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today that its Board of Directors has declared a $1.42 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.42 per share is payable on Februa |
|
| November 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-3157 |
|
| November 4, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| November 4, 2021 |
Exhibit 99.1 Medifast, Inc. Announces Third Quarter 2021 Financial Results Revenue up 52% to $413 million Company continues industry leading growth and is well positioned for 2022 BALTIMORE ? November 4, 2021 /PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, today reported results for the third quarter ended S |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13- |
|
| September 9, 2021 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, September 9, 2021/PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today that its Board of Directors has declared a $1.42 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.42 per share is payable on Novem |
|
| September 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| September 1, 2021 |
Separation Agreement dated August 26, 2021 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (the ?Agreement?) is made by and between Jason Pharmaceuticals, Inc., its affiliates, subsidiaries, predecessors, successors and assigns, and their officers, directors, trustees, employees, agents, attorneys, representatives, insurers, employee benefit plans, fiduciaries, and administrators (past, present and future) (individually and col |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| August 4, 2021 |
Medifast, Inc. Directors’ Deferred Compensation Plan (Amended and Restated) (filed herewith). Exhibit 10.2 MEDIFAST, INC. DIRECTORS? DEFERRED COMPENSATION PLAN (AMENDED AND RESTATED) ? EFFECTIVE AS OF March 18, 2021 AMENDED AS OF June 3, 2021 ? Article I.Introduction Section 1.01Purpose. This Plan is being established by Medifast, Inc. (the ?Company?) to assist the Company in attracting and retaining well-qualified directors who are not officers or employees of the Company or any subsidiar |
|
| August 4, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D. |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| August 4, 2021 |
Exhibit 99.1 Medifast, Inc. Announces Second Quarter 2021 Financial Results Revenue up 79% to $394.2 million Company positioned to deliver on 2021 goals and long-term profitable growth BALTIMORE? August 4, 2021 /PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, today reported results for the second quarter ende |
|
| June 3, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-371440 |
|
| June 3, 2021 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, June 3, 2021/PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, announced today that its Board of Directors has declared a $1.42 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.42 per share is payable on August 6, |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714405 |
|
| May 4, 2021 |
Medifast, Inc. Directors’ Deferred Compensation Plan (filed herewith). EX-10.1 2 med-20210331xex10d1.htm EX-10.1 Exhibit 10.1 MEDIFAST, INC. DIRECTORS’ DEFERRED COMPENSATION PLAN EFFECTIVE AS OF March 18, 2021 Article I.Introduction Section 1.01Purpose. This Plan is being established by Medifast, Inc. (the “Company”) to assist the Company in attracting and retaining well-qualified directors who are not officers or employees of the Company or any subsidiary (“Director |
|
| May 4, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D. |
|
| May 4, 2021 |
Medifast, Inc. Announces First Quarter 2021 Financial Results Exhibit 99.1 Medifast, Inc. Announces First Quarter 2021 Financial Results BALTIMORE? May 4, 2021 /PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA?, today reported results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights Compared to the Prior-Year Period ? Revenue increased 90.9% to $34 |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| April 19, 2021 |
EX-10.1 2 tm2113244d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version CREDIT Agreement dated as of April 13, 2021 among MEDIFAST, INC., as the Borrower The other Loan Parties Party Hereto, The Lenders Party Hereto, and CITIBANK, N.A., as Administrative Agent CITIBANK, N.A., as Sole Lead Arranger and Sole Bookrunner TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 15, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| March 18, 2021 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, March 18, 2021/PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that its Board of Directors has declared a $1.42 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.42 per share is payable on May 6, 2 |
|
| March 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| March 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Medifast Inc. Title of Class of Securities: Common Stock CUSIP Number: 58470H101 Date of Event Which Requires Filing of this Statement: February 26, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| February 26, 2021 |
Description of Securities (filed herewith). EX-4.1 2 med-20201231xex4d1.htm EX-4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Medifast, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, our common stock, par value $0.001 per share (“common stock”). References in the foll |
|
| February 26, 2021 |
Subsidiaries of Medifast, Inc. (filed herewith). EX-21.1 3 med-20201231xex21d1.htm EX-21.1 Exhibit 21.1 Subsidiaries of Medifast, Inc. Corporate Subsidiaries State of Incorporation Corporate Events, Inc. Delaware Jason Enterprises, Inc. Delaware Jason Pharmaceuticals, Inc. Maryland Jason Properties, LLC Delaware Medifast Franchise Systems, Inc. Delaware OPTAVIA, LLC Delaware OPTAVIA Health Consultation (Shanghai) Co., Ltd. Shanghai, China OPTAVI |
|
| February 26, 2021 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ?ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| February 25, 2021 |
Medifast, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Medifast, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results BALTIMORE— February 25, 2021, /PRNewswire/ - Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Highlights Compared to the Prior-Yea |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Medifast, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58470H101 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Medifast, Inc. - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2021 |
SC 13G/A 1 tv01370-medifastinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Medifast Inc. Title of Class of Securities: Common Stock CUSIP Number: 58470H101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule |
|
| January 26, 2021 |
us58470h1014012621.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 8, 2021 |
JANUARY 2021 INVESTOR PRESENTATION 1 Exhibit 99.1 JANUARY 2021 INVESTOR PRESENTATION 1 Safe Harbor Statement Certain information included in this presentation may constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward - looking statement |
|
| January 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2021 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-371 |
|
| December 10, 2020 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, December 10, 2020/PRNewswire/ - Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that its Board of Directors has declared a $1.13 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.13 per share is payable on February 5, |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| November 3, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-3157 |
|
| November 3, 2020 |
EX-10.1 2 med-20200930xex10d1.htm EX-10.1 Exhibit 10.1 MEDIFAST, INC. EXECUTIVE SEVERANCE PLAN Medifast, Inc., a Delaware corporation (the "Company"), has adopted this Medifast, Inc. Executive Severance Plan (the "Plan") to provide key employees of the Company and its affiliates and subsidiaries with severance protection under covered circumstances. ARTICLE I. DEFINITIONS AND INTERPRETATIONS Secti |
|
| November 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| November 2, 2020 |
Medifast, Inc. Announces Third Quarter 2020 Financial Results EX-99.1 2 d64755dex991.htm EX-99.1 Exhibit 99.1 Medifast, Inc. Announces Third Quarter 2020 Financial Results BALTIMORE, Nov. 2, 2020 /PRNewswire/ - Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights Compared to Prior-Year Period Rev |
|
| September 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| September 10, 2020 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, September 10, 2020/PRNewswire/ - Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that its Board of Directors has declared a $1.13 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.13 per share is payable on November 6, |
|
| August 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 Med |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| August 5, 2020 |
Medifast, Inc. Announces Second Quarter 2020 Financial Results EX-99.1 2 d54116dex991.htm EX-99.1 Exhibit 99.1 Medifast, Inc. Announces Second Quarter 2020 Financial Results BALTIMORE, Aug. 5, 2020 /PRNewswire/ - Medifast (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the second quarter ended June 30, 2020. Second Quarter 2020 Highlights Compared to Prior-Year Period Revenue inc |
|
| July 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37144 |
|
| July 20, 2020 |
Exhibit 99.1 Medifast, Inc. Names Jim Maloney as Chief Financial Officer New CFO brings more than 25 years of financial experience to fast growing health and wellness company BALTIMORE, July 20, 2020/PRNewswire/ - Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today announced that it has appointed James (Jim) Maloney as Chief Fi |
|
| July 15, 2020 |
MED / Medifast, Inc. / Engaged Capital LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Medifast, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58470H101 (CUSIP Number) glenn w. welling engag |
|
| July 10, 2020 |
MED / Medifast, Inc. / Engaged Capital LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Medifast, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58470H101 (CUSIP Number) GLENN W. WELLING ENGAG |
|
| June 16, 2020 |
Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37144 |
|
| June 16, 2020 |
Medifast, Inc. Announces Quarterly Dividend Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, June 16, 2020/PRNewswire/ - Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that its Board of Directors has declared a $1.13 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.13 per share is payable on August 6, 2020 t |
|
| May 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-31573 Me |
|
| May 5, 2020 |
Medifast, Inc. Announces First Quarter 2020 Financial Results EX-99.1 2 d830945dex991.htm EX-99.1 Exhiit 99.1 Medifast, Inc. Announces First Quarter 2020 Financial Results BALTIMORE, May 5, 2020 /PRNewswire/ - Medifast (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today reported results for the first quarter ended March 31, 2020. First Quarter 2020 Highlights Compared to Prior-Year Period Revenue increa |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714405 |
|
| April 28, 2020 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 28, 2020 |
DEFA14A 1 tm2016182-3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 3, 2020 |
EX-10.1 2 tm2014956d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) is made by and between Jason Pharmaceuticals, Inc., its affiliates, subsidiaries, predecessors, successors and assigns, and their officers, directors, trustees, employees, agents, attorneys, representatives, insurers, employee benefit plans, fiduciaries, and administrators (pa |
|
| April 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-371 |
|
| March 19, 2020 |
Medifast, Inc. Announces Quarterly Dividend EX-99.1 2 tm2013226d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Medifast, Inc. Announces Quarterly Dividend BALTIMORE, March 19, 2020/PRNewswire/ - Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that its Board of Directors has declared a $1.13 quarterly cash dividend to its stockholders. The quarterly cash dividend of |
|
| March 19, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3714 |
|
| March 5, 2020 |
Medifast Announces Chief Financial Officer Transition EX-99.1 2 tm2011789d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Medifast Announces Chief Financial Officer Transition BALTIMORE, March 4, 2020 - Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that Timothy G. Robinson, Chief Financial Officer, will be stepping down from his position at the company on March 31, 2020. Med |
|
| March 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37144 |
|
| March 2, 2020 |
Subsidiaries of Medifast, Inc. (filed herewith). Exhibit 21.1 Subsidiaries of Medifast, Inc. Corporate Subsidiaries State of Incorporation Corporate Events, Inc. Delaware Jason Enterprises, Inc. Delaware Jason Pharmaceuticals, Inc. Maryland Jason Properties, LLC Delaware Medifast Franchise Systems, Inc. Delaware Medifast Nutrition, Inc. Ontario, Canada OPTAVIA, LLC Delaware OPTAVIA Health Consultation (Shanghai) Co., Ltd. Shanghai, China OPTAVIA |
|
| March 2, 2020 |
Description of Securities (filed herewith). Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Medifast, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) our common stock, par value $0.001 per share (“common stock”), and (ii) our preferred stock purchase rights (the “Righ |
|
| March 2, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| February 26, 2020 |
Medifast, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results Exhibit 99.1 Medifast, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results Revenue increased 17% in the Fourth Quarter and 42% for the Full Year Introduces Full Year 2020 Outlook BALTIMORE, Feb. 26, 2020 PRNewswire/ - Medifast (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, which offers Lifelong Transformation, One Healthy Habit |
|
| February 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| February 14, 2020 |
MED / Medifast, Inc. / LMM LLC - MILLER VALUE PARTNERS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Medifast, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58470H101 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule |
|
| February 13, 2020 |
MED / Medifast, Inc. / Renaissance Technologies LLC Passive Investment SC 13G/A 1 med-13g20191231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Medifast, Inc. - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 12, 2020 |
MED / Medifast, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0441-medifastinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Medifast Inc Title of Class of Securities: Common Stock CUSIP Number: 58470H101 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule p |
|
| February 12, 2020 |
MED / Medifast, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* MEDIFAST INC (Name of Issuer) Common Stock (Title of Class of Securities) 58470H101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| February 4, 2020 |
MED / Medifast, Inc. / BlackRock Inc. Passive Investment us58470h1014020320.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) MEDIFAST INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 58470H101 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| January 13, 2020 |
January 2020 INVESTOR PRESENTATION EX-99.1 2 tm203250d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 January 2020 INVESTOR PRESENTATION Safe Harbor Statement Certain information included in this presentation may constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act |
|
| December 13, 2019 |
MED / Medifast, Inc. 8-A12B/A - - 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State of incorporation or organization) 13-3714405 (I.R.S. Employer Identification No.) 100 Int |
|
| December 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| December 13, 2019 |
Exhibit 4.1 FIRST AMENDMENT TO RIGHTS AGREEMENT This FIRST AMENDMENT TO RIGHTS AGREEMENT (this “Amendment”) is entered into as of December 13, 2019, by and between MEDIFAST, INC., a Delaware corporation (the “Company”), and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, a New York limited liability trust company, as rights agent (the “Rights Agent”). All capitalized terms used herein and not otherw |
|
| December 4, 2019 |
Exhibit 99.1 Medifast, Inc. Announces 51 Percent Increase in Quarterly Dividend Dividend increase follows another quarter of double-digit revenue growth BALTIMORE, December 3, 2019/PRNewswire/ - Medifast, Inc. (NYSE: MED), a leading manufacturer and distributor of clinically proven programs and healthy living products, announced today that its Board of Directors has declared a $1.13 quarterly cash |
|
| December 4, 2019 |
EX-3.1 2 tm1923867d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 MEDIFAST, INC., a Delaware Corporation AMENDED AND RESTATED BYLAWS (Amended and Restated as of June 13, 2019) TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS Section 1.1 Annual Meeting 1 Section 1.2 Notice of Business to be Brought Before an Annual Meeting 1 Section 1.3 Special Meetings 5 Section 1.4 Manner of Giving Notice 8 Section 1.5 Notice o |
|
| December 4, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission F |
|
| December 4, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2019 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-37 |
|
| November 27, 2019 |
MED / Medifast, Inc. CERT - - NYSE CERTIFICATION FILING begin 644 MED8A112719.pdf M)5!$1BTQ+C,*)79E7!E+U!A9V4O365D:6%";W@@6S @," V,3(@-SDR70HO4F]T M871E(# O4&%R96YT(#,@,"!2"B]297-O=7)C97,\/"]0)RU65MO';<1 MAF4Y5HX%6XYEU5=Y$SO5KMNE>;^\!BD*%'EI<( ^)'URT01%E$#)P?ZD5R2 ML^=0MF,@TLN< M&,%YEG*L@DF0!9%^''SK^'GS=60%N.E@H^0[ \Z*R4'(?AZU\V\35;&] M7#G,LE$N.\]"Q[DDSJ-2#E]MXZX*C[D>MO=Q#-Y[DQ:%X-6DGD].!48]MA> M;L8;T9F[]MTQGF+UD8$ZVO4)\N/TF?KK8Y*7Z(:]L7W\W'DR2:>>#&V]. |
|
| November 22, 2019 |
MEDIFAST ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN Exhibit 99.1 MEDIFAST ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN Baltimore, Md. (November 21, 2019) – Medifast (NYSE: MED) a leading manufacturer and distributor of clinically proven programs and healthy living products, today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend of one right for ea |
|
| November 22, 2019 |
MED / Medifast, Inc. 8-A12B - - 8-A12B 8-A12B 1 tm1923655d28a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation) 001-31573 (Commission File Number) |
|
| November 22, 2019 |
EX-4.1 3 tm1923655d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 MEDIFAST, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC RIGHTS AGREEMENT Dated as of November 21, 2019 TABLE OF CONTENTS Page Section 1 Definitions 1 Section 2 Appointment of Rights Agent 6 Section 3 Issue of Right Certificates 6 Section 4 Form of Right Certificates 8 Section 5 Countersignature and Registration 8 Section 6 Transfer, Spl |
|
| November 22, 2019 |
EX-3.1 2 tm1923655d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES E JUNIOR PARTICIPATING PREFERRED STOCK OF MEDIFAST, INC. (Pursuant to Section 151 of the Delaware General Corporation Law) MEDIFAST, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter called the “Corporation”), hereby certifies that the followi |
|
| November 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 MEDIFAST, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31573 (Commission File Number) 13-3 |
|
| November 18, 2019 |
MED / Medifast, Inc. / Engaged Capital LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Medifast, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58470H101 (CUSIP Number) glenn w. welling engage |
